NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Regeneron Gains on Claims its Antibody Cocktail Prevents Covid

Published 11/08/2021, 10:58 PM
© Reuters
REGN
-

By Dhirendra Tripathi

Investing.com – Regeneron Pharmaceuticals stock (NASDAQ:REGN) rose 1% on Monday after the company said a single dose of its antibody cocktail significantly reduces the risk of contracting Covid-19.

Results of a late-stage trial showed that antibody therapy, Regen-Cov, has the potential to provide long-lasting immunity against the infection, said Myron Cohen, who heads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored Covid Prevention Network.

The trial, which was fully enrolled in early 2021, allowed participants to become vaccinated if they wished once the primary efficacy treatment period (month 1) was complete.

Regen-Cov is currently authorized in the U.S. to treat people who are at high risk of serious consequences from Covid-19 who are either already infected (but not hospitalized) or in certain post-exposure settings as a precaution. It is not authorized as a substitute for vaccination against Covid in the U.S.

Regeneron is collaborating with Roche to increase global supply of the antibody cocktail, with the Swiss company responsible for development and distribution outside the U.S.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.